Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 17/20 | 0.44 |
| ▸ | PPARA | Q07869 | 17/20 | 0.44 |
| ▸ | PPARG | P37231 | 12/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29092331 | 1.00 | PPARD (0.44) | PPARDPPARAPPARGNPC1RECQL | |
| SCHEMBL28470901 | 1.00 | PPARD (0.44) | PPARDPPARAPPARGNPC1RECQL | |
| SCHEMBL29092710 | 0.92 | PPARD (0.44) | PPARDPPARAPPARG | |
| SCHEMBL29092310 | 0.92 | PPARD (0.44) | PPARDPPARAPPARG | |
| SCHEMBL29092312 | 0.92 | PPARD (0.44) | PPARDPPARAPPARG | |
| SCHEMBL29092699 | 0.90 | PPARD (0.36) | PPARDPPARAPPARG | |
| SCHEMBL29092700 | 0.90 | PPARD (0.36) | PPARDPPARAPPARG | |
| SCHEMBL29981161 | 0.90 | EGFR (0.38) | PPARDPPARAPPARG | |
| SCHEMBL29092703 | 0.90 | PPARD (0.36) | PPARDPPARAPPARG | |
| SCHEMBL28476519 | 0.90 | EGFR (0.38) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111886227-B | Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them | 柳韩洋行 | 2023-10-13 | — | — | CN | disclosed |
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2022-11-08 | — | — | US | disclosed |
| CN-111886227-A | Novel aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions containing them | 柳韩洋行 | 2020-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492335-B2 | Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same | CYP7A1, NAT1, NCOA1 | PPARD 97/4885PPARA 57/4885PPARG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.